Evaluation of a Non-cross-linked Porcine Acellular Dermal Matrix Used in Dental Surgery

NCT ID: NCT05435976

Last Updated: 2025-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-12

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS Dental membrane used in dental surgery and to identify emerging risks in comparison to clinical data related to other treatment modalities.

The present study will be a prospective multicentric non-randomized and noncontrolled trial involving 50 patients followed for 24 months. The study will be conducted in France in 4 investigational centres.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be prospective, multicentric, single-arm observational (non-interventional) to evaluate the safety and performance of the CELLIS Dental membrane used in dental surgery.

All evaluations will be performed and products used according to the usual practice and the device IFU. CELLIS Dental will be used in accordance with its approved labelling.

The study will be conducted in France in 4 investigational centres including 50 patients scheduled for dental regeneration of soft tissue defects and development of soft tissues around teeth or implants.

Each patient will participate in one assessment period including a preoperative visit followed by the surgical procedure.

Patients will return for ambulatory visits on day 15 (+/- 5 days), on month 3 (+/- 2 weeks), on month 12 (+/- 2 weeks) and on month 24 (+/-2 weeks) post-surgery.

CELLIS Dental will be implanted following standard techniques according to indications:

* Treatment of recession defects (gingival recession),
* Soft tissue augmentation around teeth and implants,
* Soft tissue grafting in combination with GBR/GTR,
* Covering/sealing of extraction sockets.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dental Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CELLIS Dental (Porcine Acellular Dermal Matrix, PADM)

Biological membranes used in dental surgery

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged ≥18 years,
* Patient with an indication of keratinized soft tissue regeneration in the buccal cavity and/or keratinized soft tissue development around teeth or implants,
* Patient being informed of his participation to the study and of the follow-up visits, and having given his written informed consent,
* Patient being informed of the porcine origin of the device in advance of the procedure.

Exclusion Criteria

* Patient with known hypersensitivity to porcine materials,
* Patient with acute or chronic infection or inflammation of the buccal cavity,
* Patient with a general illness contra-indicated for implantology, periodontology, stomatology, cranio-maxillo-facial surgery,
* Patient who is pregnant,
* Patient who is incapacitated including protected and deprived of liberty person,
* Patient having refused to participate in the study,
* Patient refusing to return for the follow-up visits.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meccellis Biotech

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rémy CAHUZAC

Role: PRINCIPAL_INVESTIGATOR

Cabinet dentaire des chênes, Saint Pierre du Mont, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cabinet dentaire Grange Blanche

Lyon, , France

Site Status

Cabinet PISB

Saint-Brieuc, , France

Site Status

CMCT (Centre Médico-Chirurgical de Touraine)

Saint-Cyr-sur-Loire, , France

Site Status

Cabinet dentaire des chênes

Saint-Pierre-du-Mont, , France

Site Status

Cabinet dentaire Saint Priest en Jarez

Saint-Priest-en-Jarez, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DS_01_CIP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Regenerative Treatment of Peri-implantitis
NCT06153212 ENROLLING_BY_INVITATION NA